PCSK9 as a therapeutic target of dyslipidemia

Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment

(2008) G. Lambert et al.   CLINICAL CHEMISTRY

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

(2008) Alexander JM Rennings et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Proprotein convertases as therapeutic targets

(2008) Michel Chrétien et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion

(2008) Jamie Cameron et al.   FEBS Journal

PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

(2008) Thilina Dewpura et al.   FEBS Journal

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

The activation and physiological functions of the proprotein convertases

(2008) N SEIDAH et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9

(2008) Sanae Kourimate et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels

(2008) Gaétan Mayer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

LNA-mediated microRNA silencing in non-human primates

(2008) Joacim Elmén et al.   NATURE

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

(2008) Cristen J Willer et al.   NATURE GENETICS

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

(2008) Sekar Kathiresan et al.   NATURE GENETICS

Molecular population genetics of PCSK9: a signature of recent positive selection

(2008) Keyue Ding et al.   Pharmacogenetics and Genomics

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Familial hypercholesterolaemia in Portugal

(2007) M. Bourbon et al.   ATHEROSCLEROSIS

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa

(2007) Vivienne M. Homer et al.   ATHEROSCLEROSIS